131
Participants
Start Date
May 31, 2007
Primary Completion Date
January 31, 2010
Study Completion Date
May 31, 2011
Lybrel
All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
Doxycycline
100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
Oracea
40-mg tablet daily for 84 days
Placebo
Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
Doxycycline 100bid x5 days at the time of bleeding
Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
Subantimicrobial doxycycline daily
Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
placebo daily
Placebo daily for the first 84 days of the study
University of Hawaii (UH), Honolulu
Oregon Health & Science University, Portland
Oregon Health and Science University
OTHER